Roth Ingunn, Juliebø-Jones Patrick, Arvei Moen Christian, Beisland Christian, Hjelle Karin M
Department of Urology, Haukeland University Hospital, Bergen, Norway.
Department of Clinical Medicine, University of Bergen, Bergen, Norway.
Eur Urol Open Sci. 2024 Mar 4;62:68-73. doi: 10.1016/j.euros.2024.02.016. eCollection 2024 Apr.
The adjustable transobturator male system (ATOMS) is an established treatment for patients with urinary incontinence after prostate surgery. Our objective was to evaluate the efficacy and the complication burdens associated with ATOMS with a focus on exploring the potential impact on previous radiotherapy (RT).
We performed a retrospective analysis for consecutive patients who underwent ATMOS implantation procedure at a tertiary center over an 11-yr study period. Outcomes of interest were dryness at 3-mo follow up, postoperative complications (≤30 d), and late treatment failures (>30 d).
A total of 118 patients underwent ATOMS surgery performed by five different surgeons. Median follow-up was 67 mo (interquartile range 41-95). The mean 24-h pad count after surgery was 1.1 (range 0-8) and the mean reduction in pad weight was 179 g (range 0-1080). There was no significant difference in the reduction in pad use between groups with and without RT (-1.7 vs -2.4; = 0.13). Multivariable analysis revealed that RT, degree of incontinence, and age were not risk factors for reoperation.
ATOMS implantation is feasible in patients who have undergone prostate RT and patients with severe stress urinary incontinence after prostate surgery. We found that RT was not a risk factor for reoperation and there was no significant difference in pad weight reduction by RT status. This study offers new insight into potential incontinence surgery for male patients with stress urinary incontinence and previous RT.
We assessed outcomes for patients who had an ATOMS (adjustable transobturator male system) device implanted to control stress urinary incontinence after prostate surgery. After implantation, 52.5% of the patients reported zero leakage and 39.9% reported only mild incontinence. Our results show that this device can improve continence after prostate surgery and is also suitable in patients who underwent radiotherapy.
可调节经闭孔男性系统(ATOMS)是前列腺手术后尿失禁患者的一种既定治疗方法。我们的目的是评估ATOMS的疗效和相关并发症负担,重点是探讨对既往放疗(RT)的潜在影响。
我们对在一家三级中心接受了11年研究期间的ATOMS植入手术的连续患者进行了回顾性分析。感兴趣的结果包括3个月随访时的干爽情况、术后并发症(≤30天)和晚期治疗失败(>30天)。
共有118例患者接受了由五位不同外科医生进行的ATOMS手术。中位随访时间为67个月(四分位间距41 - 95)。术后平均24小时尿垫使用量为1.1(范围0 - 8),尿垫重量平均减少179克(范围0 - 1080)。接受RT和未接受RT的组之间尿垫使用减少情况无显著差异(-1.7对-2.4;P = 0.13)。多变量分析显示,RT、尿失禁程度和年龄不是再次手术的危险因素。
ATOMS植入对于接受过前列腺RT的患者以及前列腺手术后严重压力性尿失禁患者是可行的。我们发现RT不是再次手术的危险因素,且根据RT状态在尿垫重量减轻方面无显著差异。本研究为有压力性尿失禁且既往接受过RT的男性患者的潜在尿失禁手术提供了新的见解。
我们评估了植入ATOMS(可调节经闭孔男性系统)装置以控制前列腺手术后压力性尿失禁的患者的结果。植入后,52.5%的患者报告零渗漏,39.9%的患者报告仅轻度尿失禁。我们的结果表明,该装置可改善前列腺手术后的控尿能力,并且也适用于接受过放疗的患者。